Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 study titled ‘A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson’s Disease.’ The study aims to assess the safety and efficacy of AAV2-GDNF gene therapy in treating moderate Parkinson’s Disease, a significant step in addressing this debilitating condition.
The intervention being tested is AAV2-GDNF gene therapy, administered through a bilateral image-guided infusion into the putamen, intended to improve symptoms in patients with moderate Parkinson’s Disease. A control group will undergo sham surgery for comparison.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, and outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new insights into Parkinson’s Disease management.
The study began on June 11, 2024, with an estimated completion date yet to be announced. The latest update was submitted on August 12, 2025, indicating ongoing recruitment and progress in the study.
This update could positively influence Bayer’s stock performance by showcasing its commitment to innovative treatments in the competitive pharmaceutical industry. Successful outcomes may enhance investor confidence and position Bayer favorably against competitors in the Parkinson’s Disease treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.